Psychotic disorders occurring for the first time in adolescents and young adults pose enormous challenges. Often diagnosis is unclear and potential treatments are not sufficiently evidence-based. Early, appropriate and consistent intervention is necessary in order to optimize outcomes in an early manifestation of a psychotic disorder and we will systematically address a range of issues in this context. Antipsychotic medications are frequently used in these diverse groups. At the same time that their use might be appropriate/efficacious in the short term, there are major unanswered questions regarding their intermediate and long-term use. What are the optimal treatments, dosing and duration of intervention to achieve remission, recovery and to prevent relapse in such individuals? Therapeutic engagement and adherence with treatment are key drivers of outcomes in these populations. As we consider the appropriateness, acceptability and benefit-to-risk ratio of antipsychotic treatments in adolescents and young adults, we also have to consider and address the potential effects of our interventions on global health and, in particular, on those illness and treatment-related factors which contribute so dramatically to increased medical morbidity and mortality in these populations (i.e. weight gain, metabolic syndrome and smoking).The mission of our Center will be to help to establish and support core enabling infrastructure and a series of investigations which can inform critical diagnostic and individual treatment decisions regarding early phase psychotic disorders. We define early phase as being within the first five years following a diagnosis or being in a major high risk category. Under the rubric of high risk and early phase psychotic disorders we include the schizophrenia and bipolar prodrome, schizophreniform disorder, psychosis NOS, substance-induced psychotic disorder, bipolar disorder with psychotic features and schizophrenia or schizoaffective disorder within five years of diagnosis. Ultimately, we hope to improve the outcome (i.e. remission, recovery, functioning, quality of life and global health) of individuals affected by any psychotic illness during a critical stage of development and individuation. Our ability to intervene appropriately, effectively and consistently in this population can have profound long-term public health consequences.
The treatment of adolescents and young adults experiencing the onset of a psychotic illness is fraught with challenges in differential diagnosis and evidence-based treatment decisions, as well as patient engagement, acceptance and adherence. The potential impact of successful early intervention on long term individual and public health outcomes is enormous.
|Rhindress, Kathryn; Ikuta, Toshikazu; Wellington, Robin et al. (2015) Delineation of hippocampal subregions using T1-weighted magnetic resonance images at 3 Tesla. Brain Struct Funct 220:3259-72|
|Vernon, Jeffrey A; Grudnikoff, Eugene; Seidman, Andrew J et al. (2014) Antidepressants for cognitive impairment in schizophrenia--a systematic review and meta-analysis. Schizophr Res 159:385-94|
|Szeszko, Philip R (2014) Aggression in schizophrenia and its relationship to neural circuitry of urgency. Am J Psychiatry 171:897-900|
|DeRosse, Pamela; Ikuta, Toshikazu; Peters, Bart D et al. (2014) Adding insult to injury: childhood and adolescent risk factors for psychosis predict lower fractional anisotropy in the superior longitudinal fasciculus in healthy adults. Psychiatry Res 224:296-302|
|Ikuta, T; Peters, B D; Guha, S et al. (2014) A schizophrenia risk gene, ZNF804A, is associated with brain white matter microstructure. Schizophr Res 155:15-20|
|Peters, Bart D; Voineskos, Aristotle N; Szeszko, Philip R et al. (2014) Brain white matter development is associated with a human-specific haplotype increasing the synthesis of long chain fatty acids. J Neurosci 34:6367-76|
|Gruner, Patricia; Vo, An; Argyelan, Miklos et al. (2014) Independent component analysis of resting state activity in pediatric obsessive-compulsive disorder. Hum Brain Mapp 35:5306-15|
|Correll, Christoph U; Olvet, Doreen M; Auther, Andrea M et al. (2014) The Bipolar Prodrome Symptom Interview and Scale-Prospective (BPSS-P): description and validation in a psychiatric sample and healthy controls. Bipolar Disord 16:505-22|
|Szeszko, Philip R; Robinson, Delbert G; Ikuta, Toshikazu et al. (2014) White matter changes associated with antipsychotic treatment in first-episode psychosis. Neuropsychopharmacology 39:1324-31|
|Peters, Bart D; Ikuta, Toshikazu; DeRosse, Pamela et al. (2014) Age-related differences in white matter tract microstructure are associated with cognitive performance from childhood to adulthood. Biol Psychiatry 75:248-56|
Showing the most recent 10 out of 29 publications